However, there was no quantification of the various effects of anti-CD137 upon CTL-mediated tumour control, so it remains unclear which enhancements to CTL effector function played the most substantial role in the improved tumour control after anti-CD137 treatment. This evidence concerns the gene TNFRSF9 and neoplasm.